How can the safety of antibody therapy for retinopathy of prematurity be improved?

Expert Rev Ophthalmol. 2023;18(2):97-99. doi: 10.1080/17469899.2023.2200934. Epub 2023 Apr 9.

Author

M Elizabeth Hartnett¹

Affiliation

¹ Stanford University, Byers Eye Institute, Stanford, CA.

No abstract available

Keywords: anti-VEGF agents; extraretinal neovascularization; retinal vascular development; safety; vascularization of peripheral retina.

Grants and funding